News

On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children. Recent published studies report up to 10.1 million U.S. children (ages 6-17) are estimated to suffer from pediatric OSA. Vivos’ DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective. It is designed to reduce nighttime snoring and treat moderate to sever

Nvidia, ARM initiated: Wall Street's top analyst calls

Strategic alliance will streamline currency conversion and improve payment efficiency in emerging markets

GE Vernova shares will likely remain on watchlists Wednesday after hitting a new record high yesterday following favorable coverage from leading investment banks. Monitor these important chart levels.

The stakes for investors are running high ahead of a historic rate cut expected from the Federal Reserve on Wednesday.

Leveraging success in Latin America to provide underbanked populations with efficient payment functions, expansion includes Burkina Faso, Cameroon, Kenya, Ivory Coast, Ghana, Senegal, South Africa, Nigeria

On Tuesday, the independent directors of the Board of 23andMe Holding Co. (NASDAQ:ME) sent a letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, providing their resignation, effective immediately. The board said, “After months of work, we have yet to receive from you a fully financed, fully diligenced, actionable proposal that is in the best interests of the non-affiliated shareholders. We believe the Special Committee and the Board have